Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 735-745

  Isla, Arantxazu ^a   Trocóniz, Iñaki F ^b   De Tejada, Ignacio López ^c   Vázquez, Silvia ^c   Canut, Andrés ^c   López, Jesús Muriel ^c   Solinís, María Ángeles ^a   Gascón, Alicia Rodríguez ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Cefoxitin; Population pharmacokinetics; Prophylaxis; Surgery

Indexed keywords

CEFOXITIN; CREATININE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON SURGERY; COLORECTAL SURGERY; COMPARTMENT MODEL; COMPUTER SIMULATION; CREATININE CLEARANCE; DEMOGRAPHY; DISEASE COURSE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM SURGERY; SURGICAL INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFOXITIN; COLON; CREATININE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RECTUM; SURGICAL PROCEDURES, ELECTIVE; SURGICAL WOUND INFECTION;

EID: 84864282976     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1206-1     Document Type: Article

References (43)

1. Aoun E, El Hachem S, Abdul-Baki H, Ayyach B, Khalifeh M, Chaar H, Kanafani ZA, Kanj SS, Sharara AI (2005) The use and abuse of antibiotics in elective colorectal surgery: the saga continues. Int J Surg 3(1):69-74 (Pubitemid 41095570)
2. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR (1999) Guideline for prevention of surgical site infection, 1999. hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 20(4):250-278
3. Nichols RL (1995) Surgical antibiotic prophylaxis. Med Clin North Am 79(3):509-522
4. Brumfitt W, Kosmidis J, Hamilton-Miller JM, Gilchrist JN (1974) Cefoxitin and cephalothin: antimicrobial activity, human pharma-cokinetics, and toxicology. Antimicrob Agents Chemother 6 (3):290-299
5. Pinder M, Bellomo R, Lipman J (2002) Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 30(2):134-144 (Pubitemid 34326595)
6. Bratzler DW, Houck PM (2004) Surgical Infection prevention guidelines writers workgroup. antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention Project. Clin Infect Dis 38(12):1706-1715 (Pubitemid 38781662)
7. Brogden RN, Heel RC, Speight TM, Avery GS (1979) Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 17(1):1-37 (Pubitemid 9078760)
8. Goodwin CS, Raftery EB, Goldberg AD, Skeggs H, Till AE, Martin CM (1974) Effects of rate of infusion and probenecid on serum levels, renal excretion, and tolerance of intravenous doses of cefoxitin in humans: comparison with cephalothin. Antimicrob Agents Chemother 6(3):338-346
9. Ko H, Cathcart KS, Griffith DL, Peters GR, Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother 33(3):356-361 (Pubitemid 19071971)
10. Kampf D, Schurig R, Korsukewitz I, Bruckner O (1981) Cefoxitin pharmacokinetics: relation to three different renal clearance studies in patients with various degrees of renal insufficiency. Antimicrob Agents Chemother 20(6):741-746 (Pubitemid 12188190)
11. Schrogie JJ, Davies RO, Yeh KC, Rogers D, Holmes GI, Skeggs H, Martin CM (1978) Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 4(B):69-78 (Pubitemid 8403806)
12. Sonneville PF, Kartodirdjo RR, Skeggs H, Till AE, Martin CM (1976) Comparative clinical pharmacology of intravenous cefoxitin and cephalothin. Eur J Clin Pharmacol 09(5-6):397-403
13. Sun H, Fadiran EO, Jones CD, Lesko L, Huang SM, Higgins K, Hu C, Machado S, Maldonado S, Williams R, Hossain M, Ette EI (1999) Population pharmacokinetics. a regulatory perspective. Clin Pharmacokinet 37(1):41-58 (Pubitemid 29366759)
14. Shah VP, Midha KK, Findlay JW et al (2000) Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 17 (12):1551-1557 (Pubitemid 32217566)
15. Food and Drug Administration (1998) Guidance for industry: bioanalytical methods validation for human studies. Center for Drug Evaluation and Research, Rockville
16. Beal SL, Sheiner LB (1992) NONMEM user's guide. University of California NONMEM Project Group, San Francisco
17. Boeckmann A, Sheiner L, Beal S (eds) (1992) NONMEN user's guide, part V. Icon Development Solutions, Ellicott City
18. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR (1998) Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26(2):207-246 (Pubitemid 28496599)
19. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17-20 (Pubitemid 46944205)
20. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558-569
21. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods: Programs Biomed 75:85-94 (Pubitemid 38798039)
22. Karlsson MO, Holford NH (2008) A tutorial on visual predictive checks (Abstr 1434). Available at: www.page-meeting.org/?abstract01434
23. Kunin CM (1966) Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin Pharmacol Ther 7(2): 166-179
24. Kunin CM, Craig WA, Kornguth M, Monson R (1973) Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 226:214-224
25. Gillett AP, Wise R (1978) Penetration of 4 cephalosporins into tissue fluid in man. Lancet 1(8071):962-964 (Pubitemid 8337718)
26. Schrogie JJ, Rogers JD, Yeh KC et al (1979) Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis 1(1):90-97
27. Carver PL, Nightingale CH, Quintiliani R (1989) Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. Antimicrob Chemother 23(1):99-106 (Pubitemid 19054108)
28. Cannon DC (1974) Kidney function tests. In: Henry RJ, Cannon DC, Winkelman JW (eds) Clinical Chemistry: principles and techniques. Harper and Row, New York
29. Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB (1980) Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother 17(5):847-855 (Pubitemid 10112536)
30. Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23(9)2036-2049
31. Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods: Programs Biomed 90:154-166
32. Pea F, Viale P, Furlanut M (2003) Antimicrobial agents in elective surgery: prophylaxis or "early therapy"? J Chemother 15(1):3-11 (Pubitemid 36349886)
33. Clinical and Laboratory Standards Institute (CLSI) (2010) Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement, M100-S20. CLSI, Wayne
34. Davis SS, Burnham WR, Wilson P, O'Brien J (1985) Use of adjuvants for enhancement of rectal absorption of cefoxitin in humans. Antimicrob Agents Chemother 28(2)211-215 (Pubitemid 15019951)
35. Reeves DS, Bullock DW, Bywater MJ, Holt HA, White LO, Thornhill DP (1981) The effect of probenecid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers. Br J Clin Pharmacol 11(4):353-359 (Pubitemid 11139987)
36. Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM (2009) Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 68(5):669-681
37. Nandy P, Samtani M, Lin R (2010) Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 54(6)2354-2359
38. Li C, Kuti JL, Nightingale CH, Nicolau P (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171-1178 (Pubitemid 44387417)
39. Scaglione F (2010) Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. Int J Antimicrob Agents 36[Suppl]:S33-S39
40. MacGowan A (2011) Revisiting beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 11(5):470-476
41. Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA (1989) Comparative antibiotic dose-effect relationships at several dosing intervals in murine pneumonitis and thigh infection models. J Infect Dis 159(2):281-292 (Pubitemid 19049368)
42. Nelson RL, Glenny AM, Song F (2009) Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev; CD001181
43. Nichols RL (1992) Prophylaxis for surgical infections. In: Gorbach SL, Bartlet JG, Blacklow NR (eds) Infectious diseases. WB Saunders, Philadelphia, pp 393-403